Table 3

Genotype-3a and -1 peptide cross-reactivity

Protein	3a Amino acid	3a Peptide	3a Peptide SFU/10⁶ PBMC	1a And/or 1b equivalent sequence		1a/1b Peptide SFU/10⁶ PBMC	3a vs 1a/1b Cross-reactivity
Core	73–90	GRSWAQPGYPWPLYGNEG	33	1a	GRTWAQPGYPWPLYGNEG	28	↓
	73–90	GRSWAQPGYPWPLYGNEG	33	1b	GRAWAQPGYPWPLYGNEGL	23	↓
	143–158	PVGGVARALAHGVRAL	50	1a = 1b	GAPLGAVARALAHGVRVL	23	↓
NS3 helicase	1423–1440	AYYRGLDVSVIPTAGDVV	267	1b	AYYRGLDVSVIPTIGDVV	0	↓
NS3 helicase	1513–1523	RPSGMFDSVVL	30	1a =1b	RPSGMFDSSVL	8	↓
NS4b	1791–1806	PAVASLMAFTASVTSPL	65	1a	PAIASLMAFTAAVTSPL	0	–
NS4b	1791–1806	PAVASLMAFTASVTSPL	65	1b	PAIASLMAFTASITSPL	0	–
NS5a	2029–2046	GVMSTRCPCGASIAGHVK	23	1a	IVHSTRHPCGESTAGHVK	30	↑
NS5a	2029–2046	GVMSTRCPCGASIAGHVK	23	1b	GIMQTTCPCGAQIAGHVK	13	↓
NS5b	2603–2618	KRALYDVIQKLSIETM	100	1b	KMALYDVVSTLPQVVM	8	↓
	2965–2975	AVRTKTKLTPLPAAGQL	33	1a	VRTKLKLTPIAAAGRLDL	0	–
	2965–2975	AVRTKTKLTPLPAAGQL	33	1b	AVRTKLKLTPIPAASQL	5	↑

T cell responses were assessed in subtype-3a patients using the positively identified subtype-3a peptides and the equivalent 1a and 1b peptides (IFN-λ ELISpot assays). Amino acids that differ from the subtype-3a peptides are shown in bold.
– loss of cross reactivity, ↓ decrease in reactivity, ↑ increase in reactivity.
IFN, interferon; PBMC, peripheral blood mononuclear cells; SFU, spot-forming units.